Phase 2 study of parsaclisib (INCB050465), a highly selective, next-generation PI3K delta inhibitor, in relapsed or refractory diffuse large B-cell lymphoma (CITADEL-202)
| Affiliation auteurs | !!!! Error affiliation !!!! |
| Titre | Phase 2 study of parsaclisib (INCB050465), a highly selective, next-generation PI3K delta inhibitor, in relapsed or refractory diffuse large B-cell lymphoma (CITADEL-202) |
| Type de publication | Journal Article |
| Year of Publication | 2021 |
| Auteurs | Coleman M, Belada D, Casasnovas R-O, Gressin R, Lee H-P, Mehta A, Munoz J, Verhoef G, Corrado C, DeMarini DJ, Zhao W, Li J, Fay K |
| Journal | LEUKEMIA & LYMPHOMA |
| Volume | 62 |
| Pagination | 368-376 |
| Date Published | JAN 28 |
| Type of Article | Article |
| ISSN | 1042-8194 |
| Mots-clés | B-cell lymphoma, DLBCL, INCB050465, Inhibitor, non-Hodgkin lymphoma, parsaclisib, PI3K&\#948 |
| Résumé | {Parsaclisib, a potent, highly selective, next-generation PI3K delta inhibitor, was evaluated as monotherapy in CITADEL-202 (NCT02998476), an open-label, multicenter, phase 2 study in patients with relapsed or refractory diffuse large B-cell lymphoma. Patients enrolled into 2 groups (A, Bruton tyrosine kinase [BTK] inhibitor naive |
| DOI | 10.1080/10428194.2020.1832660 |